Abbott BinaxNOW, Scaling COVID Testing

The Challenge

When Abbott launched BinaxNOW, the first rapid, at-home COVID-19 antigen test, in August 2020, demand immediately outstripped every production and distribution forecast. Testing sites were overwhelmed and inaccessible. Millions of Americans were waiting days for PCR results that arrived too late to be actionable. The technology existed to change the equation but the operational infrastructure to deliver it at population scale did not.

The platform that managed test distribution and result capture was still in pilot mode, built for thousands of tests, not tens of millions. Manufacturing, supply chain, regulatory compliance, eCommerce logistics and the NAVICA digital health app all needed to work in concert. No one was orchestrating the whole picture and the platform had no product strategy to match the scale of the problem.

Key Decisions

Sequence the platform rebuild around the distribution constraint, not the technology. Early pressure pushed toward building every feature simultaneously. The call was to sequence platform development around the single binding constraint: next-day distribution logistics. If fulfillment couldn’t execute, nothing else mattered. This meant deliberately deferring NAVICA app enhancements and advanced analytics until the core distribution pipeline was stable: a tradeoff that drew pushback from stakeholders who wanted everything at once.

Build the team before building the product. The platform had no dedicated cross-functional ownership. Treating this as a technical rebuild and handing it to engineering wasn’t the right call. The data showed the failures were systemic: manufacturing handoffs, regulatory gates and app workflows were all breaking independently. Recruiting across 6 workstreams before writing a single spec was the right move, because the coordination problem was more urgent than any feature gap.

Resolve the compliance-speed tradeoff structurally, not case by case. The instinct under pressure was to treat compliance reviews as one-off gates to clear quickly. Instead, working with regulatory and quality teams to embed compliance checkpoints into the production pipeline itself (at manufacturing handoff, at fulfillment and at digital result capture) added friction upfront but eliminated the recurring stop-and-restart cycles that were slowing throughput more than any single bottleneck.

Prioritize result verification over result volume in the NAVICA integration. When scoping the NAVICA app launch, there was pressure to ship result capture broadly and fast. Prioritizing verification integrity (making sure the digital result record was trustworthy enough to be accepted for travel, work and school access) over raw feature coverage was the right call. Shipping a result-capture feature that institutions wouldn’t accept would have undermined the entire distribution investment.

What I Delivered

Population management platform. Transformed the pilot-stage platform into a production system capable of supporting mass-market test distribution, with reliable workflows across manufacturing, logistics and digital result capture. Redesigned around throughput and compliance in parallel, not sequentially.

Distribution program, Built the operational backbone for next-day test delivery at national scale, coordinating across eCommerce, fulfillment and supply chain partners. The sequencing decision to stabilize distribution first before expanding platform features made this possible within the required timeline.

NAVICA app integration, Scoped and delivered Abbott’s NAVICA digital health app integration for test result capture and verification, with a deliberate focus on verification fidelity over feature breadth. Millions of Americans relied on these records for travel, work and school access.

Scaled throughput to 50M tests/month, By October 2020, the platform and distribution program were operating at 50 million tests per month. In the first half of 2021, volume scaled further to 30–90 million tests, sustaining supply continuity through the winter surge and vaccine rollout.

Outcomes

50 million tests per month by October 2020, achieved in roughly 6 weeks from platform rebuild to full production scale. The sequencing decisions made early held: distribution stabilized first, NAVICA verification shipped with integrity intact and the compliance pipeline absorbed surge volume without regulatory incident.

The NAVICA result records became recognized infrastructure for reopening: accepted for interstate travel, employer return-to-work programs, and school access protocols at a moment when no trusted rapid-testing verification standard existed. That outcome depended on the early call to prioritize verification fidelity over feature velocity. Abbott captured roughly 65% of the U.S. rapid test market at peak. The distribution flywheel that made that possible ran on institutional acceptance of NAVICA records, which in turn depended on the verification integrity call made months earlier.

In emergency health infrastructure, distribution is the product. Technology that doesn’t reach people at scale doesn’t matter.